Bessemer Group’s Apogee Therapeutics APGE Stock Holding History

Bessemer Group’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$42K	Sell	314 -191	-38%	-$17.2K	﹤0.01%	1749
2026 Q1	$42K	Sell	505 -11	-2%	-$799	﹤0.01%	1714
2025 Q4	$39K	Buy	516 +11	+2%	+$693	﹤0.01%	1700
2025 Q3	$20K	Buy	505 +465	+1,163%	+$17.8K	﹤0.01%	1688
2025 Q2	$2K	Buy	+40	New	+$1.52K	﹤0.01%	2175
2024 Q4	–	Sell	-30	Closed	-$2K	–	2449
2024 Q3	$2K	Buy	+30	New	+$1.44K	﹤0.01%	2162

Other funds holding APGE

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Bessemer Group's APGE Position: Q2 2026 in Review

Bessemer Group reduced its Apogee Therapeutics (APGE) stake by 38% in Q2 2026, selling an estimated $17.2K and leaving 314 shares worth $42K. The position accounts for ﹤0.01% of the portfolio, ranked #1749.

Bessemer Group first reported a position in APGE in Q3 2024 and has held it in 6 quarters since. 288 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

Bessemer Group held 314 shares of Apogee Therapeutics worth $42K as of Q2 2026.
Bessemer Group sold 191 Apogee Therapeutics shares in Q2 2026, an estimated $17.2K.
Apogee Therapeutics made up ﹤0.01% of Bessemer Group's portfolio in Q2 2026, its #1749 holding.
Bessemer Group first reported a position in Apogee Therapeutics in Q3 2024 and has held it in 6 quarters since.
288 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Bessemer Group's 13F filing for Q2 2026, filed 12 Aug 2026.